Lianay Gutierrez Luque
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lianay Gutierrez Luque has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Bradford G. Hill
University of Louisville
3 shared publications - Daniel C. Nguyen
Center for Cardiometabolic Science, Christina Lee Brown Envirome Institute, University of Louisville School of Medicine, Louisville, KY, USA
3 shared publications - Madison S. Taylor
Department of Medicine, Division of Environmental Medicine, Center for Cardiometabolic Science, Christina Lee Brown Envirome Institute, University of Louisville School of Medicine, Louisville, KY 40202, USA
3 shared publications - Yania Martinez-Ondaro
Center for Cardiometabolic Science, Christina Lee Brown Envirome Institute, University of Louisville School of Medicine, Louisville, KY, USA
3 shared publications - Collin K. Wells
Center for Cardiometabolic Science, Christina Lee Brown Envirome Institute, School of Medicine, 580 S Preston Street, University of Louisville , Louisville, KY 40202
2 shared publications Maleesha De Silva
2 shared publications
Latest Publications
- Open Access
- 16 October 2026
- Published by Elsevier in Redox Biology
- Vol. 98
Phasic metabolic remodeling coordinates cardiac myofibroblast differentiation and function
- 16 October 2026
- Published by Elsevier in Redox Biology
- Vol. 98
Open AccessPhasic metabolic remodeling coordinates cardiac myofibroblast differentiation and function
- Open Access
- 6 September 2026
- Published by Elsevier in SSRN Electronic Journal
Phasic metabolic remodeling coordinates cardiac myofibroblast differentiation and function
Fibroblast differentiation into matrix-producing, contractile myofibroblasts is accompanied by metabolic reprogramming, but whether these changes precede differentiation or arise from the activated phenotype remains unclear. We integrated time-resolved extracellular flux analysis, transcriptomics, stable isotope-resolved metabolomics, and metabolic interventions to define the relationship between metabolism and myofibroblast differentiation in adult mouse cardiac fibroblasts stimulated with transforming growth factor-β (TGFβ). TGFβ increased glycolysis within 1.5 h, before broad transcriptional remodeling and induction of periostin and α-smooth muscle actin. Mitochondrial respiration initially declined but increased at 48 h as the phenotype emerged, accompanied by smaller, less elongated mitochondria and greater respiratory capacity. [U-13C6]-glucose tracing revealed progressive incorporation of glucose-derived carbon into glycolytic intermediates, nucleotide sugars, and glycerol 3-phosphate, followed later by increased labeling of tricarboxylic acid cycle intermediates. TGFβ-treated fibroblasts also demonstrated enhanced insulin-stimulated glycolysis. Replacing glucose with galactose attenuated collagen and periostin induction, whereas glyceraldehyde 3-phosphate dehydrogenase inhibition prevented induction of collagen, periostin, and α-smooth muscle actin. Conversely, glucose transporter 1 or mutant PFK2 (GlycoHi) overexpression increased glycolysis without inducing myofibroblast markers. Together, these loss- and gain-of-function studies indicate that glycolytic activity is required for complete differentiation but is not sufficient to initiate the phenotype. Inhibition of mitochondrial Complex I or ATP synthase preferentially reduced collagen abundance, while glycolytic and Complex I inhibition diminished TGFβ-induced collagen gel contraction. These findings define a phasic metabolic program in which early glycolytic activation precedes transcriptional and phenotypic remodeling, whereas mitochondrial respiratory capacity increases later and distinct metabolic nodes selectively regulate collagen abundance and contractile behavior.
- 6 September 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessPhasic metabolic remodeling coordinates cardiac myofibroblast differentiation and function
Fibroblast differentiation into matrix-producing, contractile myofibroblasts is accompanied by metabolic reprogramming, but whether these changes precede differentiation or arise from the activated phenotype remains unclear. We integrated time-resolved extracellular flux analysis, transcriptomics, stable isotope-resolved metabolomics, and metabolic interventions to define the relationship between metabolism and myofibroblast differentiation in adult mouse cardiac fibroblasts stimulated with transforming growth factor-β (TGFβ). TGFβ increased glycolysis within 1.5 h, before broad transcriptional remodeling and induction of periostin and α-smooth muscle actin. Mitochondrial respiration initially declined but increased at 48 h as the phenotype emerged, accompanied by smaller, less elongated mitochondria and greater respiratory capacity. [U-13C6]-glucose tracing revealed progressive incorporation of glucose-derived carbon into glycolytic intermediates, nucleotide sugars, and glycerol 3-phosphate, followed later by increased labeling of tricarboxylic acid cycle intermediates. TGFβ-treated fibroblasts also demonstrated enhanced insulin-stimulated glycolysis. Replacing glucose with galactose attenuated collagen and periostin induction, whereas glyceraldehyde 3-phosphate dehydrogenase inhibition prevented induction of collagen, periostin, and α-smooth muscle actin. Conversely, glucose transporter 1 or mutant PFK2 (GlycoHi) overexpression increased glycolysis without inducing myofibroblast markers. Together, these loss- and gain-of-function studies indicate that glycolytic activity is required for complete differentiation but is not sufficient to initiate the phenotype. Inhibition of mitochondrial Complex I or ATP synthase preferentially reduced collagen abundance, while glycolytic and Complex I inhibition diminished TGFβ-induced collagen gel contraction. These findings define a phasic metabolic program in which early glycolytic activation precedes transcriptional and phenotypic remodeling, whereas mitochondrial respiratory capacity increases later and distinct metabolic nodes selectively regulate collagen abundance and contractile behavior.
- Open Access
- 26 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
TAK1 drives inflammatory fibroblast acquisition and shapes myocardial infarction responses in male mice
Organ function depends on communication among cell types to coordinate tissue growth and repair. Although fibroblasts are critical to this process, their role in regulating inflammatory responses to injury remain ambiguous. Here, we show that transforming growth factor β-activated kinase 1 (TAK1) is a gatekeeper of an inflammatory cardiac fibroblast phenotype. In cardiac fibroblasts, TAK1 signaling controls the acquisition of defining features of inflammatory fibroblasts, including chemokine and cytokine synthesis, lipid mediator production, metalloproteinase activity, and damage-associated molecular pattern recognition. Moreover, TAK1 propagates IL-1β and TNF-α signaling, but not TGF-β-SMAD signaling, regulating inflammatory programs by increasing chemokine secretion while decreasing lipid mediator production. Fibroblast-specific TAK1 deletion decreases neutrophil chemotaxis in vitro and immune cell recruitment after myocardial infarction in vivo, which is associated with improved cardiac remodeling and function in male mice. These results further resolve the nature and function of inflammatory fibroblasts in cardiac responses to injury and identify TAK1 signaling as a critical mediator.
- 26 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessTAK1 drives inflammatory fibroblast acquisition and shapes myocardial infarction responses in male mice
Organ function depends on communication among cell types to coordinate tissue growth and repair. Although fibroblasts are critical to this process, their role in regulating inflammatory responses to injury remain ambiguous. Here, we show that transforming growth factor β-activated kinase 1 (TAK1) is a gatekeeper of an inflammatory cardiac fibroblast phenotype. In cardiac fibroblasts, TAK1 signaling controls the acquisition of defining features of inflammatory fibroblasts, including chemokine and cytokine synthesis, lipid mediator production, metalloproteinase activity, and damage-associated molecular pattern recognition. Moreover, TAK1 propagates IL-1β and TNF-α signaling, but not TGF-β-SMAD signaling, regulating inflammatory programs by increasing chemokine secretion while decreasing lipid mediator production. Fibroblast-specific TAK1 deletion decreases neutrophil chemotaxis in vitro and immune cell recruitment after myocardial infarction in vivo, which is associated with improved cardiac remodeling and function in male mice. These results further resolve the nature and function of inflammatory fibroblasts in cardiac responses to injury and identify TAK1 signaling as a critical mediator.
- 18 October 2024
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 63 (21) , 2830-2841
Factor XIII Activation Peptide Residues Play Important Roles in Stability, Activation, and Transglutaminase Activity
A subunit of factor XIII (FXIII-A) contains a unique activation peptide (AP) that protects the catalytic triad and prevents degradation. In plasma, FXIII is activated proteolytically (FXIII-A*) by thrombin and Ca2+ cleaving AP, while in cytoplasm, it is activated nonproteolytically (FXIII-A degrees) with increased Ca2+ concentrations. This study aimed to elucidate the role of individual parts of the FXIII-A AP in protein stability, thrombin activation, and transglutaminase activity. Recombinant FXIII-A AP variants were expressed, and SDS-PAGE was used to monitor thrombin hydrolysis at the AP cleavage sites R37-G38. Transglutaminase activities were assessed by cross-linking lysine mimics to Fbg alpha C (233-425, glutamine-substrate) and monitoring reactions by mass spectrometry and in-gel fluorescence assays. FXIII-A AP variants, S19P, E23K, and D24V, degraded during purification, indicating their vital role in FXIII-A(2) stability. Mutation of P36 to L36/F36 abolished the proteolytic cleavage of AP and thus prevented activation. FXIII-A N20S and P27L exhibited slower thrombin activation, likely due to the loss of key interdomain H-bonding interactions. Except N20S and P15L/P16L, all activatable FXIII-A* variants (P15L, P16L, S19A, and P27L) showed similar cross-linking activity to WT. By contrast, FXIII-A degrees P15L, P16L, and P15L/P16L had significantly lower cross-linking activity than FXIII-A degrees WT, suggesting that loss of these prolines had a greater structural impact. In conclusion, FXIII-A AP residues that play crucial roles in FXIII-A stability, activation, and activity were identified. The interactions between these AP amino acid residues and other domains control the stability and activity of FXIII.
- 18 October 2024
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 63 (21) , 2830-2841
Factor XIII Activation Peptide Residues Play Important Roles in Stability, Activation, and Transglutaminase Activity
A subunit of factor XIII (FXIII-A) contains a unique activation peptide (AP) that protects the catalytic triad and prevents degradation. In plasma, FXIII is activated proteolytically (FXIII-A*) by thrombin and Ca2+ cleaving AP, while in cytoplasm, it is activated nonproteolytically (FXIII-A degrees) with increased Ca2+ concentrations. This study aimed to elucidate the role of individual parts of the FXIII-A AP in protein stability, thrombin activation, and transglutaminase activity. Recombinant FXIII-A AP variants were expressed, and SDS-PAGE was used to monitor thrombin hydrolysis at the AP cleavage sites R37-G38. Transglutaminase activities were assessed by cross-linking lysine mimics to Fbg alpha C (233-425, glutamine-substrate) and monitoring reactions by mass spectrometry and in-gel fluorescence assays. FXIII-A AP variants, S19P, E23K, and D24V, degraded during purification, indicating their vital role in FXIII-A(2) stability. Mutation of P36 to L36/F36 abolished the proteolytic cleavage of AP and thus prevented activation. FXIII-A N20S and P27L exhibited slower thrombin activation, likely due to the loss of key interdomain H-bonding interactions. Except N20S and P15L/P16L, all activatable FXIII-A* variants (P15L, P16L, S19A, and P27L) showed similar cross-linking activity to WT. By contrast, FXIII-A degrees P15L, P16L, and P15L/P16L had significantly lower cross-linking activity than FXIII-A degrees WT, suggesting that loss of these prolines had a greater structural impact. In conclusion, FXIII-A AP residues that play crucial roles in FXIII-A stability, activation, and activity were identified. The interactions between these AP amino acid residues and other domains control the stability and activity of FXIII.